Introduction
Ovarian cancer is the most common cause of death among gynaecological tumours in the developed world. The 5 year survival of approximately 30% is attributed to the fact that the majority of women present with late stage disease. The relative rarity of early stage tumours and the absence of any histologically de®ned premalignant stages has led to speculation that ovarian cancer may arise de novo and not through benign or borderline precursors. The paradigm established by the colorectal tumorigenesis model (Fearon and Vogelstein, 1990) suggests that malignancies arise only after the accumulation of mutations in multiple tumour suppressor genes (TSGs) as a result of the clonal expansion of successively more genetically damaged cells. In contrast, the de novo model for ovarian tumorigenesis would require that mutations in multiple TSGs occurred in rapid succession without signi®cant clonal expansion of intermediate stages.
On theoretical grounds the more likely developmental route for ovarian cancers is through benign and borderline precursors. This is supported by the observation that histologically benign tumours are frequently seen adjacent to areas of invasive cancer with many of these showing a direct transition from benign to invasive epithelium suggesting the former gave rise to the latter (Puls et al., 1992) . In addition, ovarian cancers often contain areas of diering grades, again suggesting that high-grade tumours may arise by clonal expansion of low grade tumours.
Molecular genetic analysis of ovarian cancers has demonstrated loss of heterozygosity (LOH) at numerous chromosomal locations indicative of the inactivation of TSGs. If carcinomas do arise from benign tumours, we would expect to ®nd (even if only occasionally) genetic alterations common to both benign and malignant tumours. Conversely, if benign tumours represent a distinct entity then we would expect to ®nd alterations unique to the pathway that leads to benign neoplasms.
To date there have been few LOH studies of benign ovarian tumours and all have analysed very few samples and reported very low or zero rates of LOH. In addition, many of these studies analysed DNA extracted from whole tumour biopsies which raises the possibility that an underlying high frequency of LOH is being masked by the presence of contaminating normal tissue. Consequently, there is no de®nitive estimate of how frequently LOH occurs in benign ovarian tumours or which chromosomes are involved. In this study we have addressed the limitations of earlier studies by examining a large series of benign ovarian tumours, all of which have been microdissected to remove the majority of surrounding normal stroma. Our aim was to determine whether benign epithelial ovarian tumours possess some of the genetic alterations present in ovarian carcinomas and thereby if the mechanism of ovarian tumorigenesis conforms to a progression model similar to that currently proposed for cancer of the colon.
Results
Biopsies of benign tumours generally contain only a small proportion of tumour tissue and therefore a microdissection procedure was applied to the extraction of DNA from all 31 cases. As illustrated in Figure  1 , the procedure permitted tumour tissue to be eciently harvested with very little contamination from surrounding normal tissue. These DNA samples were assessed for LOH using 14 microsatellite markers encompassing six chromosome arms as listed in Table  1 . These loci were chosen because they are the sites of frequent LOH in malignant ovarian tumours (Dodson et al., 1993; Engle®eld et al., 1994; Orphanos et al., 1995) . The LOH results together with the histological data for each tumour are summarized in Table 2 .
A high frequency of LOH was detected with 15/31 (48%) cases showing LOH with at least one marker when using the DNA extracted from microdissected tumours. An example of LOH detected in the microdissected tumours is shown in Figure 2 . In contrast, only 5/31 (16%) cases showed LOH when the DNA extracted en bloc from fresh snap-frozen tissues was used with the false negative cases all containing less than 20% tumour (not shown). Thus microdissection has resulted in a threefold increase in the rate of detection of LOH.
LOH was detected on all the chromosomes examined but was more frequent on 7p and 9p with 26% of cases showing LOH. Interestingly, three of the seven tumours showing LOH on chromosome 7 retained heterozygosity at loci¯anking the areas of LOH implying the presence of interstitial deletions. This is signi®cant as the presence of such deletions in benign tumours are likely to re¯ect speci®c TSG inactivtion events rather than generalized genomic instability. A more detailed analysis of these and additional cases could facilitate the re®nement of the location of the putative TSG(s).
Analysis of exons 5 ± 8 of TP53 by single stranded conformational polymorphism analysis (SSCP) was performed on all 31 tumuors. A band shift was detected in exon 5 in DNA extracted from the glandular but not the stromal component of tumour 276 (Figure 3 ). DNA sequencing revealed a G to T substitution in codon 157, causing a missense change of valine to phenylalanine (Figure 4) . No SSCP band shifts were detected in any of the remaining tumours.
Discussion
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In contrast to the relatively frequent LOH detected on chromosomes 7 and 9, LOH on chromosome 17p, in the vicinity of the TP53 gene, was rare in benign tumours. This is consistent with many reports indicating that TP53 inactivation is in general a late event in ovarian tumorigenesis (Berchuck et al., 1994; Kim et al., 1995) . Signi®cantly, one of our benign tumours (number 276) did harbour a TP53 mutation in codon 157. The diagnosis of a purely mucinous cystadenoma was con®rmed following meticulous reexamination of all the original archival blocks including the one from which the DNA was extracted and represents the ®rst report of a TP53 mutation in a solitary benign ovarian tumour.
TP53 mutations have previously been reported in benign tumours but only when adjacent to malignant ovarian tumours (Zheng et al., 1995) . Zheng et al. found no evidence of TP53 mutations in 16 solitary benign tumours and therefore concluded that the six benign tumours harbouring TP53 mutations were atypical in that they carried a genetic predisposition to carcinogenesis not present in ordinary cystadenomas. However our ®nding of genetic alterations, including a TP53 mutation among our collection of benign tumours suggests that all benign tumours may carry a genetic disposition to carcinogenesis. This is further supported by the ®ndings of Salazar et al. (1996) who demonstrated a signi®cantly increased frequency of unanticipated benign and borderline tumours in ovaries remove prophylactically from 20 women with a high risk of developing ovarian cancer based on a strong family history and/or positive linkage to BRCA1. They suggested that presence of these feature represented a characteristic histologic pre-neoplastic phenotype.
In summary, by the application of a microdissection technique we have been able to demonstrate frequent LOH on chromosome arms 7p and 9p, as well as lower rate of LOH on 6p, 7q and 11q in solitary benign ovarian tumours. These ®ndings are consistent with the paradigm that malignant ovarian tumours may develop through benign precursors and provides a framework for future analysis of malignant potential of benign ovarian tumours.
Materials and methods

Source of tumour DNA
Fresh snap-frozen ovarian tumours and matched blood were obtained from women undergoing surgery for ovarian tumours at the Princess Anne Hospital, Southampton, UK.
Preparation of tumour and normal DNA
Tumour biopsies were analysed by haematoxylin and eosin staining to con®rm histological diagnosis and to assess percentage of tumour and stroma. Initially DNA was extracted from pieces of the tumour biopsy that contained the highest percentage of tumour according to our previously published protocol (Foulkes et al., 1993) . The percentage of tumour in these biopsies was low, ranging between 10 ± 30%. Therefore microdissection of the tumour biopsies was also performed to ensure minimal normal tissue contamination. Five sequential 5 mm sections were cut from the same fresh snap-frozen tumour specimens used for the en bloc extractions, and mounted on poly-L lysine slides and then stained with haematoxylin and eosin using standard techniques. One section was then covered and evaluated by microscopy to locate the normal and tumour components. Using this slide as a template, the areas of epithelium and adjacent stroma were carefully scraped from the uncovered slides with a 25 gauge needle and collected in separate tubes and incubated in 100 ml of lysis buer (50 mM Tris, 1 mM EDTA, 0.5% Tween 20) and proteinase K (200 mg/ml) for 12 ± 24 h at 558C. The samples were then heated to 958C for 10 min to destroy proteinase K activity and stored at 48C.
Loss of heterozygosity studies
Detection of loss of heterozygosity was accomplished using 14 microsatellite markers on chromosomal arms 6q, 7p, 7q, 9p, 11q and 17p as listed in Table 1 . PCR was carried out using 10 ± 200 ng of en bloc extracted DNA or 1 ml of the microdissected tumour DNA. All PCR reactions were performed in 10 ml volumes containing 1 mCi of [a-32 P]dCTP as described previously . Annealing temperatures (T8C) within the range of 50 ± 608C were optimized for each primer pair. The standard cycle conditions for PCR ampli®cation was as follows: 1 cycle of 958C for 5 min; 38 cycles of 958C for 1 min, T8C for 1 min and 728C for 1 min; 1 cycle of 728C for 5 min. Ampli®ed products were separated on 8% nondenaturing polyacrylamide gels run in a sequencing gel apparatus. Following overnight electrophoresis at 300 volts the gels were dried and the individuals alleles identi®ed following radiographic exposure on X-ray ®lm (Kodak X-AR). Only cases where visual assessment was sucient to clearly discriminate between loss and retention of heterozygosity were recorded.
SSCP and sequencing analysis of TP53 PCR ampli®cation of exons 5 ± 8 of TP53 were performed using the primers and conditions described by Milner et al. (1993) . SSCP analysis of the samples was performed as previously described . Tumour samples showing abnormal band shifts were repeated together with matching normal DNA to ensure that it was not due to a germline polymorphism. DNA sequencing was performed using a dideoxy termination protocol (Foulkes et al., 1995) .
